OCT 22, 2020 7:00 AM PDT

Migraines: Dark Times and (Pharmaceutical) Rays of Hope

WRITTEN BY: Tara Fernandes


Despite being commonly used interchangeably, headaches and migraines are worlds apart. Migraines are by far much more prolonged and debilitating, encompassing a range of accompanying symptoms from throbbing pain and light sensitivity to nausea and vomiting. The pathophysiology of this condition is complex and identifying potential therapeutic targets has, for a long time, eluded neuroscientists. Among the challenges is that nobody knows what really causes migraines.

The current working theory is that the trigeminovascular system (a neural connection that innervates blood vessels in the head) is a major player. Recurrent activation and sensitization of this pathway alters the excitability of the brain, resulting in the hypersensitivity to light, sounds, and even smells. 

For the estimated 16 percent of the worldwide population that suffers from migraines, a silver lining has come in the form of a suite of migraine therapeutics that have recently entered the clinic. One of these is a migraine drug called erenumab (Aimovig) — a monoclonal antibody drug derived from natural immune systems. The antibody prevents both episodic as well as chronic migraines by blocking the activity of calcitonin gene-related peptide (CGRP), a potent peptide produced by neurons. Elevated levels of CGRP have been linked to a range of conditions including migraine, hypertension, and cardiac failure.

A recent study conducted by Australian scientists has highlighted the true potential of Erenumab at relieving severe migraine attacks in chronic sufferers. The study tracked migraine incidences in a cohort of almost 200 patients. After taking the drug, almost 60 percent of them had at least halved the number of migraines they experienced per month.

“These drugs represent a significant advance in migraine care, and with many patients describing them as ‘life-changing’, they bring new hope to many living with migraine disease,” said the study’s lead author Dr. Elspeth Hutton from Monash University.

Sources: Headache, AJMC, Nature.  


 

About the Author
You May Also Like
AUG 20, 2022
Health & Medicine
What is the Connection Between Interpersonal Rejection and Increased COVID Precautions?
AUG 20, 2022
What is the Connection Between Interpersonal Rejection and Increased COVID Precautions?
Some people who may not normally worry about disease may take greater steps to protect themselves against COVID-19 if th ...
SEP 06, 2022
Microbiology
The return of Monkeypox: the need for new research and immunodiagnostics
SEP 06, 2022
The return of Monkeypox: the need for new research and immunodiagnostics
Introduction Monkeypox virus (MPXV) is an old virus that has recently grabbed attention because of its emergence in unco ...
SEP 18, 2022
Immunology
Surprising Roles for Hormones in Wound Repair
SEP 18, 2022
Surprising Roles for Hormones in Wound Repair
When we get a bacterial infection in our skin, our immune system responds. It's been thought that inflammatory cells ...
OCT 13, 2022
Cell & Molecular Biology
How the Tumor Microenvironment Can Disarm Immunity
OCT 13, 2022
How the Tumor Microenvironment Can Disarm Immunity
Cancer is basically what happens when cells start growing and dividing uncontrollably, and it gets worse when those canc ...
NOV 21, 2022
Immunology
Unusual, Ultrapotent Antibody Against Zika is Discovered
NOV 21, 2022
Unusual, Ultrapotent Antibody Against Zika is Discovered
Zika virus is transmitted by the Aedes aegypti mosquito and can cause a mild illness in otherwise healthy adults. But wh ...
NOV 22, 2022
Microbiology
Flu Killed Mice Eating a Processed Diet, but Spared Those on Grains
NOV 22, 2022
Flu Killed Mice Eating a Processed Diet, but Spared Those on Grains
When researchers have studied infections in animal models, they have typically focused on the pathogen and the host. But ...
Loading Comments...